LIVIVO - Search results -

Search results

Result 1 - 10 of total 71

Search options

Article ; Online: Post-acute care nursing home deaths in the COVID era: Potential for attribution bias.

Gomolin, Irving H / Hartley, Douglas A / Polsky, Bruce

Journal of the American Geriatrics Society

2021 Volume 69, Issue 6, Page(s) 1450–1452

MeSH term(s)	Aged ; Bias ; COVID-19/mortality ; Humans ; Nursing Homes ; Subacute Care
Language	English
Publishing date	2021-03-26
Publishing country	United States
Document type	Letter
ZDB-ID	80363-7
ISSN	1532-5415 ; 0002-8614
ISSN (online)	1532-5415
ISSN	0002-8614
DOI	10.1111/jgs.17132
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Absence of COVID-19 Disease Among Chronically Ventilated Nursing Home Patients.

Gomolin, Irving H / Krichmar, Grigoriy / Siskind, David / Divers, Jasmin / Polsky, Bruce

Journal of the American Medical Directors Association

2021 Volume 22, Issue 12, Page(s) 2500–2503

Abstract: Objective: To describe the experience of COVID-19 disease among chronically ventilated and nonventilated nursing home patients living in 3 separate nursing homes.: Design: Observational study of death, respiratory illness and COVID-19 polymerase ... ...

Abstract	Objective: To describe the experience of COVID-19 disease among chronically ventilated and nonventilated nursing home patients living in 3 separate nursing homes. Design: Observational study of death, respiratory illness and COVID-19 polymerase chain reaction (PCR) results among residents and staff during nursing home outbreaks in 2020. Setting and participants: 93 chronically ventilated nursing home patients and 1151 nonventilated patients living among 3 separate nursing homes on Long Island, New York, as of March 15, 2020. Illness, PCR results, and antibody studies among staff are also reported. Measurements: Data were collected on death rate among chronically ventilated and nonventilated patients between March 15 and May 15, 2020, compared to the same time in 2019; prevalence of PCR positivity among ventilated and nonventilated patients in 2020; reported illness, PCR positivity, and antibody among staff. Results: Total numbers of deaths among chronically ventilated nursing home patients during this time frame were similar to the analogous period 1 year earlier (9 of 93 in 2020 vs 8 of 100 in 2019, P = .8), whereas deaths among nonventilated patients were greatly increased (214 of 1151 in 2020 vs 55 of 1189 in 2019, P < .001). No ventilated patient deaths were clinically judged to be COVID-19 related. No clusters of COVID-19 illness could be demonstrated among ventilated patients. Surveillance PCR testing of ventilator patients failed to reveal COVID-19 positivity (none of 84 ventilator patients vs 81 of 971 nonventilator patients, P < .002). Illness and evidence of COVID-19 infection was demonstrated among staff working both in nonventilator and in ventilator units. Conclusions and implications: COVID-19 infection resulted in illness and death among nonventilated nursing home residents as well as among staff. This was not observed among chronically ventilated patients. The mechanics of chronic ventilation appears to protect chronically ventilated patients from COVID-19 disease.
MeSH term(s)	COVID-19 ; Disease Outbreaks ; Humans ; Nursing Homes ; SARS-CoV-2 ; Skilled Nursing Facilities
Language	English
Publishing date	2021-09-29
Publishing country	United States
Document type	Journal Article ; Observational Study
ZDB-ID	2171030-2
ISSN	1538-9375 ; 1525-8610
ISSN (online)	1538-9375
ISSN	1525-8610
DOI	10.1016/j.jamda.2021.09.019
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5971: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.

Onuoha, Erica N / Leff, Jared A / Schackman, Bruce R / McCollister, Kathryn E / Polsky, Daniel / Murphy, Sean M

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

2021 Volume 24, Issue 7, Page(s) 1068–1083

Abstract: Objective: The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration-approved medications for treatment of opioid use disorder: methadone, buprenorphine, and injectable extended- ... ...

Abstract	Objective: The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration-approved medications for treatment of opioid use disorder: methadone, buprenorphine, and injectable extended-release naltrexone (XR-NTX). The comparative effectiveness and cost vary considerably among these 3 medications. Economic evaluations provide evidence that help stakeholders efficiently allocate scarce resources. Our objective was to summarize recent health economic evidence of pharmacologic treatment of opioid use disorder interventions. Methods: We searched PubMed for peer-reviewed studies in English from August 2015 through December 2019 as an update to a 2015 review. We used the Drummond checklist to evaluate and categorize economic evaluation study quality. We summarized results by economic evaluation methodology and pharmacologic treatment modality. Results: We identified 105 articles as potentially relevant and included 21 (4 cost-offset studies and 17 cost-effectiveness/cost-benefit studies). We found strengthened evidence on buprenorphine and methadone, indicating that these treatments are economically advantageous compared with no pharmacotherapy, but found limited evidence on XR-NTX. Only half of the cost-effectiveness studies used a generic preference-based measure of effectiveness, limiting broad comparison across diseases/disorders. The disease/disorder-specific cost-effectiveness measures vary widely, suggesting a lack of consensus on the value of substance use disorder treatment. Conclusion: We found studies that provide new evidence supporting the cost-effectiveness of buprenorphine compared with no pharmacotherapy. We found a lack of evidence supporting superior economic value for buprenorphine versus methadone, suggesting that both are attractive alternatives. Further economic research is needed on XR-NTX, as well as other emerging pharmacotherapies, treatment modalities, and dosage forms.
MeSH term(s)	Adolescent ; Adult ; Cost-Benefit Analysis ; Drug Therapy/economics ; Humans ; Middle Aged ; Opioid-Related Disorders/drug therapy ; United States ; Young Adult
Language	English
Publishing date	2021-05-08
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Systematic Review
ZDB-ID	1471745-1
ISSN	1524-4733 ; 1098-3015
ISSN (online)	1524-4733
ISSN	1098-3015
DOI	10.1016/j.jval.2020.12.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5904: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study.

R Nagler, Arielle / Horwitz, Leora I / Jones, Simon / Petrilli, Christopher M / Iturrate, Eduardo / Lighter, Jennifer L / Phillips, Michael / Bosworth, Brian P / Polsky, Bruce / Volpicelli, Frank M / Dapkins, Isaac / Viswanathan, Anand / François, Fritz / Kalkut, Gary

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

2022 Volume 79, Issue 24, Page(s) 2222–2229

Abstract: Purpose: Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to ...

Abstract	Purpose: Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. Methods: A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19-specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. Results: A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
MeSH term(s)	Humans ; COVID-19/drug therapy ; COVID-19 Testing ; Retrospective Studies ; Antineoplastic Agents, Immunological ; Antibodies, Monoclonal/therapeutic use
Chemical Substances	imdevimab (2Z3DQD2JHM) ; etesevimab (N7Q9NLF11I) ; casirivimab (J0FI6WE1QN) ; bamlanivimab (45I6OFJ8QH) ; Antineoplastic Agents, Immunological ; Antibodies, Monoclonal
Language	English
Publishing date	2022-10-15
Publishing country	England
Document type	Journal Article
ZDB-ID	1224627-x
ISSN	1535-2900 ; 1079-2082
ISSN (online)	1535-2900
ISSN	1079-2082
DOI	10.1093/ajhp/zxac295
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 419: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Conference proceedings ; Audio / Video: Report from the XVII International AIDS Conference in Mexico City, August 3-8, 2008

Polsky, Bruce

(NCME ; no. 875)

2008

Abstract: ... best practice, lessons learned, and gaps in knowledge are addressed. In this video, Drs. Bruce Polsky and Jin S ...

Title variant	Report from the Seventeenth International AIDS Conference in Mexico City, August 3-8, 2008 ; Report from the 17th International AIDS Conference in Mexido City, August 3-8, 2008
Event/congress	International Conference on AIDS (17th, 2008, MexicoCity)
Author's details	Bruce W. Polsky, Jin S. Suh
Series title	NCME ; no. 875
Abstract	Approximately 1.2 million people in the United States are living with HIV/AIDs today. Using new technology, the Centers for Disease Control and Prevention estimates the yearly incidence of HIV disease since 1990 to be approximately 56,000 cases per year, representing an almost 40% increase compared with earlier estimates. Advances in HIV/AIDS treatment have substantially reduced AIDS-related morbidity and mortality and extended the lives of many. New treatments, however, are not a cure and do not benefit or reach people with HIV. The epidemic continues to have a disproportionate impact on certain populations, particularly racial and ethnic minorities. The XVII International AIDS Conference, which was held in Mexico City from August 3-8, 2008, provides a forum in which key scientific and practice-based research, best practice, lessons learned, and gaps in knowledge are addressed. In this video, Drs. Bruce Polsky and Jin S. Suh discuss state-of-the-art data, as presented at the conference, on the epidemiology of HIV, the revised International AIDS Society-USA treatment guidelines, the use of antiretroviral agents in the treatment-naive and -expreienced patients, new antiretroviral agents, and antiretroviral-associated complications.
MeSH term(s)	Acquired Immunodeficiency Syndrome ; HIV Infections ; Anti-Retroviral Agents/therapeutic use
Language	English
Size	1 DVD-video (60 min.) :, sd., col. ;, 4 3/4 in.
Publisher	Network for Continuing Medical Education
Publishing place	Secaucus, N.J
Document type	Book ; Conference proceedings ; Audio / Video
Note	ACCME-accredited sponsor: the Network for Continuing Medical Education ; approved for up to 2 AMA PRA Category 1 credits; for 1 prescribed credit (AAFP); AMA Category 1 credit accepted (AAPA); and up to 2 credit hours in Category 2-A (AOA). ; Bibliographical data supplied by NCME. ; "Released October 31, 2008."
Database	Catalogue of the US National Library of Medicine (NLM)

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book ; Audio / Video: HCV and HIV coinfection

Polsky, Bruce

(NCME ; no. 862)

2007

Abstract: ... of liver disease than are individuals infected with HIV alone. In this program, Dr. Polsky discusses evidence-based ...

Institution	Network for Continuing Medical Education
Author's details	Bruce W. Polsky
Series title	NCME ; no. 862
Abstract	More than 170 million people worldwide have chronic hepatitis C virus (HCV) infection and approximately 40 million individuals are infected with the human immunodeficiency virus (HIV). Coinfection with HIV and HCV is common and affects 15% to 30% of HIV-infected individuals in the United States. Immunosuppression can increase the risk of progressive liver disease in HIV patients coinfected with HCV. In addition, coinfected patients are 3 times more likely to develop cirrhosis and 4.6 times more likely to die of liver disease than are individuals infected with HIV alone. In this program, Dr. Polsky discusses evidence-based strategies for optimizing the management of patients coinfected with HCV and HIV.
MeSH term(s)	Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; HIV Infections/complications ; HIV Infections/drug therapy ; Evidence-Based Medicine/methods
Language	English
Size	1 DVD-video (60 min.) :, sd., col. ;, 4 3/4 in.
Publisher	Network for Continuing Medical Education
Publishing place	Secaucus, N.J
Document type	Book ; Audio / Video
Note	ACCME-accredited sponsor: the Network for Continuing Medical Education ; approved for up to 2 AMA PRA Category 1 credits; for 1 prescribed credit (AAFP); AMA Category 1 credit accepted (AAPA); and up to 2 credit hours in Category 2-A (AOA). ; Bibliographical data supplied by NCME. ; "Released February 28, 2007."
Database	Catalogue of the US National Library of Medicine (NLM)

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients.

Reidenberg, Bruce E / Wanner, Christoph / Polsky, Bruce / Castanheira, Mariana / Shelip, Alla / Stalleicken, Dirk / Pfaffle, Antony E

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

2017 Volume 37, Issue 4, Page(s) 661–663

Abstract: Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to ... ...

Abstract	Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls.
MeSH term(s)	Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Calcium Citrate/administration & dosage ; Calcium Citrate/adverse effects ; Calcium Citrate/therapeutic use ; Catheter-Related Infections/drug therapy ; Catheter-Related Infections/epidemiology ; Catheter-Related Infections/prevention & control ; Central Venous Catheters ; Drug Combinations ; Germany/epidemiology ; Heparin/administration & dosage ; Heparin/adverse effects ; Heparin/therapeutic use ; Humans ; Product Surveillance, Postmarketing ; Renal Dialysis ; Taurine/administration & dosage ; Taurine/adverse effects ; Taurine/analogs & derivatives ; Taurine/therapeutic use ; Thiadiazines/administration & dosage ; Thiadiazines/adverse effects ; Thiadiazines/therapeutic use ; Thrombosis/drug therapy ; Thrombosis/epidemiology ; Thrombosis/prevention & control
Chemical Substances	Anti-Bacterial Agents ; Drug Combinations ; Thiadiazines ; Taurine (1EQV5MLY3D) ; taurolidine (8OBZ1M4V3V) ; Heparin (9005-49-6) ; Calcium Citrate (MLM29U2X85)
Language	English
Publishing date	2017-12-06
Publishing country	Germany
Document type	Journal Article
ZDB-ID	603155-9
ISSN	1435-4373 ; 0934-9723 ; 0722-2211
ISSN (online)	1435-4373
ISSN	0934-9723 ; 0722-2211
DOI	10.1007/s10096-017-3157-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1732: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Hemorrhagic bullous lesions due to Bacillus cereus in a cirrhotic patient.

Rios, Liliana / Paniz Mondolfi, Alberto Enrique / Slova, Denisa / Polsky, Bruce / Sordillo, Emilia Mia

Cutis

2014 Volume 94, Issue 6, Page(s) E15–7

Language	English
Publishing date	2014-12-24
Publishing country	United States
Document type	Letter
ZDB-ID	391840-3
ISSN	2326-6929 ; 0011-4162 ; 0151-9522
ISSN (online)	2326-6929
ISSN	0011-4162 ; 0151-9522
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1315: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 44: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Effect of Entry Regulation in the Health Care Sector: the Case of Home Health.

Polsky, Daniel / David, Guy / Yang, Jianing / Kinosian, Bruce / Werner, Rachel

Journal of public economics

2014 Volume 110, Page(s) 1–14

Abstract: The consequences of government regulation in the post-acute care sector are not well understood. We examine the effect of entry regulation on quality of care in home health care by analyzing the universe of hospital discharges during 2006 for publicly ... ...

Abstract	The consequences of government regulation in the post-acute care sector are not well understood. We examine the effect of entry regulation on quality of care in home health care by analyzing the universe of hospital discharges during 2006 for publicly insured beneficiaries (about 4.5 million) and subsequent home health admissions to determine whether there is a significant difference in home health utilization, hospital readmission rates, and health care expenditures in states with and without Certificate of Need laws (CON) regulating entry. We identify these effects by looking across regulated and nonregulated states within Hospital Referral Regions, which characterize well-defined health care markets and frequently cross state boundaries. We find that CON states use home health less frequently, but system-wide rehospitalization rates, overall Medicare expenditures, and home health practice patterns are similar. Removing CON for home health would have negligible system-wide effects on health care costs and quality.
Language	English
Publishing date	2014-02-04
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1460611-2
ISSN	1879-2316 ; 0047-2727
ISSN (online)	1879-2316
ISSN	0047-2727
DOI	10.1016/j.jpubeco.2013.11.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Book: AIDS

Schmitt, Heinz-Josef / Polsky, Bruce

Virologie, Epidemiologie und Management

1987

Author's details	Heinz-J. Schmitt u. Bruce Polsky
Keywords	Acquired Immunodeficiency Syndrome ; Aids
Subject	Acquired immune deficiency syndrome ; Erworbenes Immundefektsyndrom
Language	German
Size	95 S. : Ill., graph. Darst.
Publisher	Marseille
Publishing place	München
Publishing country	Germany
Document type	Book
Note	Literaturverz. S. 85 - 90
HBZ-ID	HT002978150
ISBN	3-88616-022-X ; 978-3-88616-022-8
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
1987 A 2112	order for loan	Magazin
1987 A 2112a	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito